ERBB2 and breast cancer: Except for the recent approval of trastuzumab deruxtecan in pre-treated patients with HER2 + GC [6], other HER2-targeted agents have not been proven to be effective in patients with HER2+ GC during the last decade, even though these agents are effective and currently used in patients with HER2+ BC.